An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

NCT05686629 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Novel COVID-19-Infected Pneumonia

Interventions

DRUG: Jaktinib hydrochloride tablets

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd